NASDAQ: ONCOOnconetix Inc Stock
$0.13+0.00 (+0%)
Updated Apr 19, 2024
ONCO Price
$0.13
Fair Value Price
N/A
Market Cap
$2.84M
52 Week Low
$0.12
52 Week High
$1.58
P/E
-0.06x
P/B
-0.51x
P/S
57.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$58.47k
Earnings
-$37.41M
Gross Margin
-1,927.9%
Operating Margin
-62,859.25%
Profit Margin
-63,986.5%
Debt to Equity
-3.91
Operating Cash Flow
-$14M
Beta
0.74
Next Earnings
May 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ONCO Overview
Blue Water Vaccines, Inc. is a biotechnology company developing vaccines for infectious diseases. The company's pipeline includes BWV-101, a flu vaccine, BWV-102, an H1 pre-pandemic vaccine, BWV-201, a streptococcus pneumoniae-induced acute otitis media vaccine, BWV-301, a norovirus-rotavirus vaccine, and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, OH.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ONCO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONCO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ONCO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ONCO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ONCO due diligence checks available for Premium users.
Be the first to know about important ONCO news, forecast changes, insider trades & much more!
ONCO News
Valuation
ONCO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
15.81x
Market
40.51x
ONCO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.51x
Industry
5.74x
ONCO's financial health
Profit margin
Revenue
$58.5k
Net Income
-$22.4M
Profit Margin
-38,229.5%
ONCO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ONCO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$87.5M
Liabilities
$21.9M
Debt to equity
-3.91
ONCO's short-term liabilities ($17.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONCO's short-term assets ($5.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONCO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ONCO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
$1.2M
Financing
$0.0
ONCO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ONCO vs Biotech Stocks
Onconetix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.